PLASMA CELL MYELOMA

This early-phase trial tests whether a vaccine made from a protein called survivin can safely boost the immune system to fight multiple myeloma. The study involves 18 patients who have already responded to initial treatment and are taking lenalidomide as maintenance therapy. The …

This study tests a new COVID-19 vaccine (GEO-CM04S1) in 63 adults with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. The goal is to see if this vaccine triggers a stronger immune response than standard mRNA vaccines, potentially offe…

This phase 3 trial enrolled over 1,000 people with newly diagnosed multiple myeloma to compare two drug combinations: VRd (bortezomib, lenalidomide, dexamethasone) and CRd (carfilzomib, lenalidomide, dexamethasone). After initial treatment, participants received either limited or…

This phase 2 trial tests whether daratumumab, an antibody that targets cancer cells, can improve outcomes for people with multiple myeloma after they receive a stem cell transplant. The study involves 31 participants and is currently active but not recruiting. The main goal is to…

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This study offers continued treatment with isatuximab for adults with multiple myeloma who are still benefiting from the drug after finishing an earlier clinical trial. The main goal is to monitor long-term safety. About 70 participants will receive the drug as long as it helps t…

This phase II trial is testing whether adding elotuzumab to standard lenalidomide maintenance therapy can help keep multiple myeloma from returning after a stem cell transplant. About 113 patients who have already had a transplant using their own stem cells will receive the combi…

This study looks at whether people with multiple myeloma who have been in a deep remission (called MRD-negative) for at least 3 years can stop their maintenance therapy and just be monitored closely. The goal is to see if stopping treatment keeps the cancer under control for at l…

This study tests a new drug called iberdomide combined with three standard treatments (daratumumab, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to find the best dose and see if the combination can kill more cancer cells. About 49 a…

This study tests whether a combination of belantamab mafodotin (a targeted chemotherapy) and lenalidomide can eliminate any remaining cancer cells in multiple myeloma patients who still have detectable disease after a stem cell transplant. The trial enrolls 4 adults with multiple…

This phase 3 study tests whether adding isatuximab to standard lenalidomide and dexamethasone can delay progression to active multiple myeloma in people with high-risk smoldering myeloma. About 337 participants will receive either the three-drug combo or the two-drug standard. Th…

This study tests whether adding isatuximab to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who cannot have a stem cell transplant live longer without their cancer worsening. About 475 participant…

This study tests whether adding a drug called cyclophosphamide after a stem cell transplant can reduce the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers or seve…

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This study tests a decision aid website designed to help women with cancer make informed choices about preserving their fertility before treatment. About 130 women with newly diagnosed breast, colorectal, or reproductive system cancers, or lymphoma/myeloma, will use the website o…

This study looks at how well the heart, lungs, and muscles work together in people who have had a stem cell transplant. Researchers want to find out why transplant survivors have a higher risk of heart disease. About 350 adults with blood cancers will be followed for two years af…